U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935941) titled 'A Phase I Study of HLX109 in Healthy Participants' on Oct. 18.

Brief Summary: This study is a randomized, double-Blind, single ascending dose, phase I clinical study to evaluate safety, tolerability and pharmacokinetic profiles of HLX109 in healthy participants

Study Start Date: Nov. 18

Study Type: INTERVENTIONAL

Condition: First in Man Study to Evaluate Initial Safety

Intervention: DRUG: HLX109

HLX109: A mg, SC, single dose

DRUG: HLX109

HLX109: B mg, SC, single dose

DRUG: HLX109

HLX109: C mg, SC, single dose

DRUG: HLX109

HLX109: D mg, SC, single dose

DRUG: HLX109

HLX109: E mg, SC, single dose

DRUG: HLX109

HLX109: F...